Cara Therapeutics, Inc. 69C.F Stock
Cara Therapeutics, Inc. Price Chart
Cara Therapeutics, Inc. 69C.F Financial and Trading Overview
Cara Therapeutics, Inc. stock price | 0.7 EUR |
Previous Close | 3.04 EUR |
Open | 2.9 EUR |
Bid | 2.9 EUR x 150000 |
Ask | 3 EUR x 140000 |
Day's Range | 2.9 - 2.9 EUR |
52 Week Range | 2.73 - 11.99 EUR |
Volume | 100 EUR |
Avg. Volume | 2 EUR |
Market Cap | 156.55M EUR |
Beta (5Y Monthly) | 0.861619 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.08 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 26.33 EUR |
69C.F Valuation Measures
Enterprise Value | 51.17M EUR |
Trailing P/E | N/A |
Forward P/E | -2.3577237 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.6203525 |
Price/Book (mrq) | 1.1457922 |
Enterprise Value/Revenue | 1.183 |
Enterprise Value/EBITDA | -0.588 |
Trading Information
Cara Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.861619 |
52-Week Change | -56.88% |
S&P500 52-Week Change | 20.43% |
52 Week High | 11.99 EUR |
52 Week Low | 2.73 EUR |
50-Day Moving Average | 3.71 EUR |
200-Day Moving Average | 8.19 EUR |
69C.F Share Statistics
Avg. Volume (3 month) | 2 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 53.98M |
Float | 45.25M |
Short Ratio | N/A |
% Held by Insiders | 14.36% |
% Held by Institutions | 65.33% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -195.15% |
Operating Margin (ttm) | -201.82% |
Gross Margin | -134.90% |
EBITDA Margin | -201.26% |
Management Effectiveness
Return on Assets (ttm) | -28.92% |
Return on Equity (ttm) | -49.53% |
Income Statement
Revenue (ttm) | 43.24M EUR |
Revenue Per Share (ttm) | 0.81 EUR |
Quarterly Revenue Growth (yoy) | 28.69% |
Gross Profit (ttm) | -56141000 EUR |
EBITDA | -87031000 EUR |
Net Income Avi to Common (ttm) | -84390000 EUR |
Diluted EPS (ttm) | -1.47 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 114.28M EUR |
Total Cash Per Share (mrq) | 2.12 EUR |
Total Debt (mrq) | 1.46M EUR |
Total Debt/Equity (mrq) | 1.07 EUR |
Current Ratio (mrq) | 8.554 |
Book Value Per Share (mrq) | 2.531 |
Cash Flow Statement
Operating Cash Flow (ttm) | -87823000 EUR |
Levered Free Cash Flow (ttm) | -56472248 EUR |
Profile of Cara Therapeutics, Inc.
Country | Germany |
State | CT |
City | Stamford |
Address | 4 Stamford Plaza |
ZIP | 06902 |
Phone | 203 406 3700 |
Website | https://www.caratherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 106 |
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.
Q&A For Cara Therapeutics, Inc. Stock
What is a current 69C.F stock price?
Cara Therapeutics, Inc. 69C.F stock price today per share is 0.7 EUR.
How to purchase Cara Therapeutics, Inc. stock?
You can buy 69C.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cara Therapeutics, Inc.?
The stock symbol or ticker of Cara Therapeutics, Inc. is 69C.F.
Which industry does the Cara Therapeutics, Inc. company belong to?
The Cara Therapeutics, Inc. industry is Biotechnology.
How many shares does Cara Therapeutics, Inc. have in circulation?
The max supply of Cara Therapeutics, Inc. shares is 61.4M.
What is Cara Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Cara Therapeutics, Inc. PE Ratio is now.
What was Cara Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Cara Therapeutics, Inc. EPS is -2.08 EUR over the trailing 12 months.
Which sector does the Cara Therapeutics, Inc. company belong to?
The Cara Therapeutics, Inc. sector is Healthcare.